APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Drugs

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Selected research

Industry Growth & Trends

Global Microbiome Drugs Industry Growth and Trends Forecast to 2032

30 December 2025110 pages

Choose your research edition.

Industry ResearchMicrobiome Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Microbiome Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

According to APO Research, the global Microbiome Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Report Scope

Read the full market overview

This report provides a structured, data-driven view of the global Microbiome Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Microbiome Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Microbiome Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Microbiome Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Microbiome Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Microbiome Drugs Market by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Microbiome Drugs Segment by Type

Oral Dosage Form

Enteric Capsules

Microbiome Drugs Segment by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Microbiome Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Microbiome Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Microbiome Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Microbiome Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Microbiome Drugs Market Share by Region (2021-2026) Table 4. Global Microbiome Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Microbiome Drugs Market Share by Region (2027-2032) Table 6. Global Microbiome Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Microbiome Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Microbiome Drugs Market Size Share by Type (2021-2026) Table 9. Global Microbiome Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Microbiome Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Microbiome Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Microbiome Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Microbiome Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Microbiome Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Microbiome Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Microbiome Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Microbiome Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Microbiome Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Microbiome Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Microbiome Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Microbiome Drugs Market Size by Symptom (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Microbiome Drugs Market Size by Symptom (2021-2026) & (US$ Million) Table 23. Global Microbiome Drugs Market Size Share by Symptom (2021-2026) Table 24. Global Microbiome Drugs Market Size Forecasted by Symptom (2027-2032) & (US$ Million) Table 25. Global Microbiome Drugs Market Size Share Forecasted by Symptom (2027-2032) Table 26. North America Microbiome Drugs Market Size Breakdown by Symptom (2021-2026) & (US$ Million) Table 27. North America Microbiome Drugs Market Size Breakdown by Symptom (2027-2032) & (US$ Million) Table 28. Europe Microbiome Drugs Market Size Breakdown by Symptom (2021-2026) & (US$ Million) Table 29. Europe Microbiome Drugs Market Size Breakdown by Symptom (2027-2032) & (US$ Million) Table 30. Asia-Pacific Microbiome Drugs Market Size Breakdown by Symptom (2021-2026) & (US$ Million) Table 31. Asia-Pacific Microbiome Drugs Market Size Breakdown by Symptom (2027-2032) & (US$ Million) Table 32. Latin America Microbiome Drugs Market Size Breakdown by Symptom (2021-2026) & (US$ Million) Table 33. Latin America Microbiome Drugs Market Size Breakdown by Symptom (2027-2032) & (US$ Million) Table 34. Middle East and Africa Microbiome Drugs Market Size Breakdown by Symptom (2021-2026) & (US$ Million) Table 35. Middle East and Africa Microbiome Drugs Market Size Breakdown by Symptom (2027-2032) & (US$ Million) Table 36. Microbiome Drugs Industry Trends Table 37. Microbiome Drugs Industry Drivers Table 38. Microbiome Drugs Industry Opportunities and Challenges Table 39. Microbiome Drugs Industry Restraints Table 40. Global Microbiome Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Microbiome Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Microbiome Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Microbiome Drugs Key Company Headquarters & Area Served Table 44. Global Microbiome Drugs Company, Product Type & Application Table 45. Global Microbiome Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Microbiome Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Seres Therapeutics Company Information Table 49. Seres Therapeutics Business Overview Table 50. Seres Therapeutics Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Seres Therapeutics Microbiome Drugs Product Portfolio Table 52. Seres Therapeutics Recent Development Table 53. Assembly Biosciences Company Information Table 54. Assembly Biosciences Business Overview Table 55. Assembly Biosciences Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Assembly Biosciences Microbiome Drugs Product Portfolio Table 57. Assembly Biosciences Recent Development Table 58. Synthetic Biologics Company Information Table 59. Synthetic Biologics Business Overview Table 60. Synthetic Biologics Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Synthetic Biologics Microbiome Drugs Product Portfolio Table 62. Synthetic Biologics Recent Development Table 63. Interxon Company Information Table 64. Interxon Business Overview Table 65. Interxon Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Interxon Microbiome Drugs Product Portfolio Table 67. Interxon Recent Development Table 68. PureTech Company Information Table 69. PureTech Business Overview Table 70. PureTech Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. PureTech Microbiome Drugs Product Portfolio Table 72. PureTech Recent Development Table 73. Synlogic Company Information Table 74. Synlogic Business Overview Table 75. Synlogic Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Synlogic Microbiome Drugs Product Portfolio Table 77. Synlogic Recent Development Table 78. Enterome BioScience Company Information Table 79. Enterome BioScience Business Overview Table 80. Enterome BioScience Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Enterome BioScience Microbiome Drugs Product Portfolio Table 82. Enterome BioScience Recent Development Table 83. 4D Pharma Company Information Table 84. 4D Pharma Business Overview Table 85. 4D Pharma Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. 4D Pharma Microbiome Drugs Product Portfolio Table 87. 4D Pharma Recent Development Table 88. Second Genome Company Information Table 89. Second Genome Business Overview Table 90. Second Genome Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Second Genome Microbiome Drugs Product Portfolio Table 92. Second Genome Recent Development Table 93. AOBiome Company Information Table 94. AOBiome Business Overview Table 95. AOBiome Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. AOBiome Microbiome Drugs Product Portfolio Table 97. AOBiome Recent Development Table 98. Rebiotix Company Information Table 99. Rebiotix Business Overview Table 100. Rebiotix Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Rebiotix Microbiome Drugs Product Portfolio Table 102. Rebiotix Recent Development Table 103. Metabiomics Company Information Table 104. Metabiomics Business Overview Table 105. Metabiomics Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Metabiomics Microbiome Drugs Product Portfolio Table 107. Metabiomics Recent Development Table 108. Ritter Pharmaceuticals Company Information Table 109. Ritter Pharmaceuticals Business Overview Table 110. Ritter Pharmaceuticals Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Ritter Pharmaceuticals Microbiome Drugs Product Portfolio Table 112. Ritter Pharmaceuticals Recent Development Table 113. Symberix Company Information Table 114. Symberix Business Overview Table 115. Symberix Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Symberix Microbiome Drugs Product Portfolio Table 117. Symberix Recent Development Table 118. OpenBiome Company Information Table 119. OpenBiome Business Overview Table 120. OpenBiome Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. OpenBiome Microbiome Drugs Product Portfolio Table 122. OpenBiome Recent Development Table 123. Azitra Company Information Table 124. Azitra Business Overview Table 125. Azitra Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Azitra Microbiome Drugs Product Portfolio Table 127. Azitra Recent Development Table 128. Osel Company Information Table 129. Osel Business Overview Table 130. Osel Microbiome Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Osel Microbiome Drugs Product Portfolio Table 132. Osel Recent Development Table 133. North America Microbiome Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Microbiome Drugs Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Microbiome Drugs Market Share by Country (2021-2026) Table 136. North America Microbiome Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Microbiome Drugs Market Share Forecast by Country (2027-2032) Table 138. Europe Microbiome Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Europe Microbiome Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. Europe Microbiome Drugs Market Share by Country (2021-2026) Table 141. Europe Microbiome Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Europe Microbiome Drugs Market Share Forecast by Country (2027-2032) Table 143. Asia-Pacific Microbiome Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Asia-Pacific Microbiome Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Asia-Pacific Microbiome Drugs Market Share by Country (2021-2026) Table 146. Asia-Pacific Microbiome Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Asia-Pacific Microbiome Drugs Market Share Forecast by Country (2027-2032) Table 148. Latin America Microbiome Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Latin America Microbiome Drugs Market Size by Country (2021-2026) & (US$ Million) Table 150. Latin America Microbiome Drugs Market Share by Country (2021-2026) Table 151. Latin America Microbiome Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Latin America Microbiome Drugs Market Share Forecast by Country (2027-2032) Table 153. Middle East & Africa Microbiome Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East & Africa Microbiome Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East & Africa Microbiome Drugs Market Share by Country (2021-2026) Table 156. Middle East & Africa Microbiome Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East & Africa Microbiome Drugs Market Share Forecast by Country (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Microbiome Drugs Product Image Figure 3. Global Microbiome Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Microbiome Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Microbiome Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Microbiome Drugs Market Share by Region (2021-2032) Figure 7. North America Microbiome Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Microbiome Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Microbiome Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Microbiome Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Microbiome Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oral Dosage Form Image Figure 13. Global Oral Dosage Form Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Enteric Capsules Image Figure 15. Global Enteric Capsules Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Microbiome Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Microbiome Drugs Market Share by Type 2025 VS 2032 Figure 18. North America Microbiome Drugs Market Size Share by Type (2021-2032) Figure 19. Europe Microbiome Drugs Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Microbiome Drugs Market Size Share by Type (2021-2032) Figure 21. Latin America Microbiome Drugs Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Microbiome Drugs Market Size Share by Type (2021-2032) Figure 23. Gastrointestinal Disorders Image Figure 24. Global Gastrointestinal Disorders Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Autoimmune Disorders Image Figure 26. Global Autoimmune Disorders Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Diabetes Image Figure 28. Global Diabetes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Cancer Image Figure 30. Global Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Others Image Figure 32. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Microbiome Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Microbiome Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Microbiome Drugs Market Size Share by Application (2021-2032) Figure 36. Europe Microbiome Drugs Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Microbiome Drugs Market Size Share by Application (2021-2032) Figure 38. Latin America Microbiome Drugs Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Microbiome Drugs Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Microbiome Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Microbiome Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Microbiome Drugs Market Share by Country (2021-2032) Figure 45. Europe Microbiome Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Microbiome Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Microbiome Drugs Market Share by Country (2021-2032) Figure 48. Asia-Pacific Microbiome Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Microbiome Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Microbiome Drugs Market Share by Country (2021-2032) Figure 51. Latin America Microbiome Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Microbiome Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Microbiome Drugs Market Share by Country (2021-2032) Figure 54. Middle East & Africa Microbiome Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Microbiome Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Microbiome Drugs Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Dosage Form
  • Enteric Capsules
Applications
  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • Rebiotix
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Osel

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Microbiome Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Microbiome Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Microbiome Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Microbiome Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Microbiome Drugs Market Size (2021-2032)
  8. 1.5.1 North America Microbiome Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Microbiome Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Microbiome Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Microbiome Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Microbiome Drugs Market Size Growth Rate (2021-2032)
2 Microbiome Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oral Dosage Form
  3. 2.1.2 Enteric Capsules
  4. 2.2 Global Microbiome Drugs Market Size by Type
  5. 2.2.1 Global Microbiome Drugs Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Microbiome Drugs Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Microbiome Drugs Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Microbiome Drugs Market Size by Regions
  9. 2.3.1 North America Microbiome Drugs Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Microbiome Drugs Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Microbiome Drugs Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Microbiome Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Microbiome Drugs Market Size Breakdown by Type (2021-2026)
3 Microbiome Drugs Market by Symptom
  1. 3.1 Type Introduction
  2. 3.1.1 Gastrointestinal Disorders
  3. 3.1.2 Autoimmune Disorders
  4. 3.1.3 Diabetes
  5. 3.1.4 Cancer
  6. 3.1.5 Others
  7. 3.2 Global Microbiome Drugs Market Size by Symptom
  8. 3.2.1 Global Microbiome Drugs Market Size Overview by Symptom (2021-2032)
  9. 3.2.2 Global Microbiome Drugs Historic Market Size Review by Symptom (2021-2026)
  10. 3.2.3 Global Microbiome Drugs Market Size Forecasted by Symptom (2027-2032)
  11. 3.3 Global Microbiome Drugs Market Size by Regions
  12. 3.3.1 North America Microbiome Drugs Market Size Breakdown by Symptom (2021-2026)
  13. 3.3.2 Europe Microbiome Drugs Market Size Breakdown by Symptom (2021-2026)
  14. 3.3.3 Asia-Pacific Microbiome Drugs Market Size Breakdown by Symptom (2021-2026)
  15. 3.3.4 South America Microbiome Drugs Market Size Breakdown by Symptom (2021-2026)
  16. 3.3.5 Middle East and Africa Microbiome Drugs Market Size Breakdown by Symptom (2021-2026)
4 Global Market Dynamics
  1. 4.1 Microbiome Drugs Industry Trends
  2. 4.2 Microbiome Drugs Industry Drivers
  3. 4.3 Microbiome Drugs Industry Opportunities and Challenges
  4. 4.4 Microbiome Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Microbiome Drugs Revenue (2021-2026)
  2. 5.2 Global Microbiome Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Microbiome Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Microbiome Drugs Company, Product Type & Application
  5. 5.5 Global Microbiome Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Microbiome Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Microbiome Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Microbiome Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Seres Therapeutics
  2. 6.1.1 Seres Therapeutics Company Information
  3. 6.1.2 Seres Therapeutics Business Overview
  4. 6.1.3 Seres Therapeutics Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
  6. 6.1.5 Seres Therapeutics Recent Developments
  7. 6.2 Assembly Biosciences
  8. 6.2.1 Assembly Biosciences Company Information
  9. 6.2.2 Assembly Biosciences Business Overview
  10. 6.2.3 Assembly Biosciences Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
  12. 6.2.5 Assembly Biosciences Recent Developments
  13. 6.3 Synthetic Biologics
  14. 6.3.1 Synthetic Biologics Company Information
  15. 6.3.2 Synthetic Biologics Business Overview
  16. 6.3.3 Synthetic Biologics Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
  18. 6.3.5 Synthetic Biologics Recent Developments
  19. 6.4 Interxon
  20. 6.4.1 Interxon Company Information
  21. 6.4.2 Interxon Business Overview
  22. 6.4.3 Interxon Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Interxon Microbiome Drugs Product Portfolio
  24. 6.4.5 Interxon Recent Developments
  25. 6.5 PureTech
  26. 6.5.1 PureTech Company Information
  27. 6.5.2 PureTech Business Overview
  28. 6.5.3 PureTech Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 PureTech Microbiome Drugs Product Portfolio
  30. 6.5.5 PureTech Recent Developments
  31. 6.6 Synlogic
  32. 6.6.1 Synlogic Company Information
  33. 6.6.2 Synlogic Business Overview
  34. 6.6.3 Synlogic Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Synlogic Microbiome Drugs Product Portfolio
  36. 6.6.5 Synlogic Recent Developments
  37. 6.7 Enterome BioScience
  38. 6.7.1 Enterome BioScience Company Information
  39. 6.7.2 Enterome BioScience Business Overview
  40. 6.7.3 Enterome BioScience Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
  42. 6.7.5 Enterome BioScience Recent Developments
  43. 6.8 4D Pharma
  44. 6.8.1 4D Pharma Company Information
  45. 6.8.2 4D Pharma Business Overview
  46. 6.8.3 4D Pharma Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 4D Pharma Microbiome Drugs Product Portfolio
  48. 6.8.5 4D Pharma Recent Developments
  49. 6.9 Second Genome
  50. 6.9.1 Second Genome Company Information
  51. 6.9.2 Second Genome Business Overview
  52. 6.9.3 Second Genome Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Second Genome Microbiome Drugs Product Portfolio
  54. 6.9.5 Second Genome Recent Developments
  55. 6.10 AOBiome
  56. 6.10.1 AOBiome Company Information
  57. 6.10.2 AOBiome Business Overview
  58. 6.10.3 AOBiome Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 AOBiome Microbiome Drugs Product Portfolio
  60. 6.10.5 AOBiome Recent Developments
  61. 6.11 Rebiotix
  62. 6.11.1 Rebiotix Company Information
  63. 6.11.2 Rebiotix Business Overview
  64. 6.11.3 Rebiotix Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Rebiotix Microbiome Drugs Product Portfolio
  66. 6.11.5 Rebiotix Recent Developments
  67. 6.12 Metabiomics
  68. 6.12.1 Metabiomics Company Information
  69. 6.12.2 Metabiomics Business Overview
  70. 6.12.3 Metabiomics Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Metabiomics Microbiome Drugs Product Portfolio
  72. 6.12.5 Metabiomics Recent Developments
  73. 6.13 Ritter Pharmaceuticals
  74. 6.13.1 Ritter Pharmaceuticals Company Information
  75. 6.13.2 Ritter Pharmaceuticals Business Overview
  76. 6.13.3 Ritter Pharmaceuticals Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
  78. 6.13.5 Ritter Pharmaceuticals Recent Developments
  79. 6.14 Symberix
  80. 6.14.1 Symberix Company Information
  81. 6.14.2 Symberix Business Overview
  82. 6.14.3 Symberix Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Symberix Microbiome Drugs Product Portfolio
  84. 6.14.5 Symberix Recent Developments
  85. 6.15 OpenBiome
  86. 6.15.1 OpenBiome Company Information
  87. 6.15.2 OpenBiome Business Overview
  88. 6.15.3 OpenBiome Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 OpenBiome Microbiome Drugs Product Portfolio
  90. 6.15.5 OpenBiome Recent Developments
  91. 6.16 Azitra
  92. 6.16.1 Azitra Company Information
  93. 6.16.2 Azitra Business Overview
  94. 6.16.3 Azitra Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Azitra Microbiome Drugs Product Portfolio
  96. 6.16.5 Azitra Recent Developments
  97. 6.17 Osel
  98. 6.17.1 Osel Company Information
  99. 6.17.2 Osel Business Overview
  100. 6.17.3 Osel Microbiome Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Osel Microbiome Drugs Product Portfolio
  102. 6.17.5 Osel Recent Developments
7 North America
  1. 7.1 North America Microbiome Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Microbiome Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Microbiome Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Microbiome Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Microbiome Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Microbiome Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Microbiome Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Microbiome Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Microbiome Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Microbiome Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Microbiome Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Microbiome Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Microbiome Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Microbiome Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Microbiome Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst